MaxCyte Inc (MXCT)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $122.87M
Last updated: Nov 17, 2026 at 11:05 AM ET
MaxCyte Inc (MXCT) Earnings: Report Dates and Results
MaxCyte (MXCT) is expected to report earnings on Mar 12, 2027. In the quarter ended Sep 30, 2026, MaxCyte reported EPS of -$0.05, above the -$0.08 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
MXCT has an expected report date of Mar 12, 2027.
MXCT Earnings Call
The latest MXCT earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 23 quarters below that had an estimate, MXCT beat 16, missed 3 and matched 4. Revenue for the quarter ended Sep 30, 2026 was $10.15M, up 48.6% from $6.83M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.05 | -$0.08 | -$0.09 - -$0.08 | +37.50% | Beat | N/A | 3 | 0 up, 1 down | Nov 10, 2026 | $10.15M |
| Jun 30, 2026 | -$0.08 | -$0.12 | -$0.12 - -$0.08 | +33.33% | Beat | N/A | 3 | 0 up, 1 down | Aug 12, 2026 | $7.27M |
| Mar 31, 2026 | -$0.04 | -$0.07 | N/A | +31.69% | Beat | N/A | 2 | 0 up, 1 down | May 12, 2026 | $9.65M |
| Dec 31, 2025 | -$0.06 | -$0.08 | -$0.09 - -$0.07 | +25.00% | Beat | N/A | 3 | 3 up, 1 down | Mar 24, 2026 | $7.30M |
| Sep 30, 2025 | -$0.09 | -$0.10 | -$0.12 - -$0.07 | +10.00% | Beat | N/A | 5 | 0 up, 3 down | Nov 12, 2025 | $6.83M |
| Jun 30, 2025 | -$0.12 | -$0.10 | -$0.11 - -$0.09 | -20.00% | Miss | N/A | 5 | 0 up, 1 down | Aug 6, 2025 | $8.51M |
| Mar 31, 2025 | -$0.10 | -$0.10 | -$0.12 - -$0.09 | 0.00% | In line | N/A | 4 | 1 up, 0 down | May 7, 2025 | $10.39M |
| Dec 31, 2024 | -$0.10 | -$0.12 | -$0.15 - -$0.10 | +16.67% | Beat | N/A | 4 | 0 up, 0 down | Mar 11, 2025 | $8.69M |
| Sep 30, 2024 | -$0.11 | -$0.12 | -$0.15 - -$0.11 | +8.33% | Beat | N/A | 6 | 0 up, 0 down | Nov 6, 2024 | $8.16M |
| Jun 30, 2024 | -$0.09 | -$0.13 | -$0.15 - -$0.12 | +30.77% | Beat | N/A | 6 | 0 up, 0 down | Aug 6, 2024 | $10.43M |
| Mar 31, 2024 | -$0.09 | -$0.13 | -$0.15 - -$0.12 | +30.77% | Beat | N/A | 6 | 0 up, 0 down | May 7, 2024 | $11.34M |
| Dec 31, 2023 | -$0.05 | -$0.07 | -$0.10 - -$0.05 | +28.57% | Beat | N/A | 5 | 0 up, 0 down | Mar 12, 2024 | $15.66M |
| Sep 30, 2023 | -$0.11 | -$0.10 | -$0.11 - -$0.08 | -10.00% | Miss | N/A | 5 | 0 up, 0 down | Nov 8, 2023 | $8.00M |
| Jun 30, 2023 | -$0.10 | -$0.10 | -$0.12 - -$0.08 | 0.00% | In line | N/A | 5 | 0 up, 0 down | Aug 9, 2023 | $9.04M |
| Mar 31, 2023 | -$0.11 | -$0.11 | -$0.12 - -$0.11 | 0.00% | In line | N/A | 5 | 0 up, 0 down | May 10, 2023 | $8.58M |
| Dec 31, 2022 | -$0.05 | -$0.07 | -$0.08 - -$0.05 | +28.57% | Beat | N/A | 5 | 1 up, 0 down | Mar 15, 2023 | $12.42M |
| Sep 30, 2022 | -$0.06 | -$0.08 | -$0.10 - -$0.06 | +25.00% | Beat | N/A | 5 | 1 up, 0 down | Nov 9, 2022 | $10.64M |
| Jun 30, 2022 | -$0.08 | -$0.07 | -$0.09 - -$0.07 | -14.29% | Miss | N/A | 5 | 0 up, 0 down | Aug 10, 2022 | $9.61M |
| Mar 31, 2022 | -$0.04 | -$0.07 | -$0.07 - -$0.04 | +42.86% | Beat | N/A | 5 | 4 up, 0 down | May 9, 2022 | $11.59M |
| Dec 31, 2021 | -$0.05 | -$0.05 | -$0.08 - -$0.02 | 0.00% | In line | N/A | 5 | 0 up, 0 down | Mar 22, 2022 | $10.15M |
| Sep 30, 2021 | -$0.03 | -$0.05 | -$0.07 - -$0.02 | +40.00% | Beat | N/A | 5 | 0 up, 0 down | Nov 10, 2021 | $10.14M |
| Jun 30, 2021 | -$0.05 | -$0.06 | -$0.08 - -$0.05 | +16.67% | Beat | N/A | 4 | N/A | Jul 30, 2021 | $7.11M |
| Mar 31, 2021 | -$0.07 | -$0.10 | N/A | +30.00% | Beat | N/A | N/A | N/A | Jun 16, 2021 | $6.49M |
| Dec 31, 2020 | -$0.09 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2021 | $8.51M |
| Sep 30, 2020 | -$0.04 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 31, 2020 | $6.76M |
| Jun 30, 2020 | -$0.04 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 30, 2020 | $5.15M |
| Dec 31, 2019 | -$0.05 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2020 | $6.62M |
| Sep 30, 2019 | -$0.03 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 31, 2019 | $6.62M |
| Jun 30, 2019 | -$0.03 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 30, 2019 | $4.19M |
| Mar 31, 2019 | -$0.09 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 29, 2019 | $4.19M |
| Dec 31, 2018 | -$0.09 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2019 | $4.87M |
| Sep 30, 2018 | -$0.04 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 31, 2018 | $4.87M |
| Jun 30, 2018 | -$0.04 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 30, 2018 | $3.46M |
| Mar 31, 2018 | -$0.05 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 29, 2018 | $3.46M |
| Dec 31, 2017 | -$0.05 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2018 | $3.89M |
| Sep 30, 2017 | -$0.06 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 31, 2017 | $3.89M |
| Jun 30, 2017 | -$0.06 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 30, 2017 | $3.11M |
| Mar 31, 2017 | -$0.05 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 29, 2017 | $3.11M |
| Dec 31, 2016 | -$0.05 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2017 | $3.40M |
| Sep 30, 2016 | -$0.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 31, 2016 | $3.40M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.37, after -$0.39 the year before. It was -$0.13 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.37 | N/A |
| Dec 31, 2024 | -$0.39 | N/A |
| Dec 31, 2023 | -$0.37 | N/A |
| Dec 31, 2022 | -$0.23 | N/A |
| Dec 31, 2021 | -$0.20 | N/A |
| Dec 31, 2020 | -$0.16 | N/A |
| Dec 31, 2019 | -$0.20 | N/A |
| Dec 31, 2018 | -$0.21 | N/A |
| Dec 31, 2017 | -$0.20 | N/A |
| Dec 31, 2016 | -$0.13 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,800 words across 9 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 7,835 | 9 | |
| 2026Q2 | Jun 30, 2026 | 5,755 | 10 | |
| 2026Q1 | Mar 31, 2026 | 4,846 | 12 | |
| 2025Q4 | Dec 31, 2025 | 6,494 | 11 | |
| 2025Q3 | Sep 30, 2025 | 6,427 | 10 | |
| 2025Q2 | Jun 30, 2025 | 5,210 | 8 | |
| 2025Q1 | Mar 31, 2025 | 6,210 | 9 | |
| 2024Q4 | Dec 31, 2024 | 5,819 | 10 |
2026Q3 Earnings Call
Opening remarks
Maher Masoud President and Chief Executive Officer Thank you, Erik. Hello, everyone, and thank you for joining MaxCyte's third-quarter 2026 earnings call. Before I turn to our results, I want to highlight the announcement we made today, which I believe is one of the most exciting moments in our company's history. Following a competitive process, we have entered into a definitive agreement to acquire Akron Bio from Arkline Investment Management. Akron Bio is a leading supplier of GMP-grade reagents and ancillary materials, including cytokines, growth factors, cell culture media, and cryopreservation solutions, used in the cell therapy manufacturing steps immediately before and after cell engineering, including electroporation. Akron Bio differentiates itself through its regulatory-grade quality and documentation, along with ready-to-use product formats that simplify and connect directly to cell therapy manufacturing workflows. Like MaxCyte, Akron Bio is specified in its customers' regulated processes, with drug master files, or DMFs, referenced in their IND and BLA submissions. Once specified in, which typically occurs in late-stage preclinical development, Akron Bio's products become increasingly difficult to displace as programs advance through clinical development and commercialization. Akron Bio supports four commercially approved therapies, including one with a leading global pharma company, and supports four additional programs with registrational pathways. With Akron Bio, MaxCyte triples its exposure to attractive commercial and registrational programs that are nearing approval. Beyond these late-stage assets, the combined company will be embedded in over 95 clinical-stage programs, including more than 85 from Akron Bio, providing a broad pipeline for potential future commercial opportunities. As part of our extensive diligence process, we conducted a detailed, program-by-program assessment of Akron Bio's portfolio, evaluating individual development timelines, progression toward commercialization, and long-term revenue opportunities. This bottom-up approach reinforced our conviction in the quality of its portfolio and its long-term growth potential. Akron Bio also brings meaningful scale, expanding our commercial revenue footprint and extending our reach across the cell therapy workflow, including both viral and nonviral therapies. Akron Bio's revenue is expected to be $28 million for 2026, and importantly, 80% to 85% of 2025 revenue was generated from specified-in customers, including 40% to 45% from commercial-stage customers. Both metrics highlight the durable and recurring nature of its revenue base. Furthermore, Akron Bio is expected to generate approximately $7 million to $8 million of EBITDA in 2026 and is cash-flow positive today, with an efficient cost structure. The acquisition will accelerate MaxCyte's path to profitability, which Parmeet will cover in more detail. Stepping back, I cannot be more excited by what this combination means for MaxCyte's next chapter.
Frequently Asked Questions About MXCT
When is MaxCyte's next earnings date?
MaxCyte's next earnings report is expected for Mar 12, 2027.
Did MXCT beat earnings estimates last quarter?
Yes. MaxCyte reported EPS of -$0.05 for the quarter ended Sep 30, 2026, above the -$0.08 estimate, a 37.50% surprise.
What EPS do analysts expect from MXCT next quarter?
The consensus EPS estimate for MaxCyte for the quarter ending Dec 31, 2026 is -$0.08 from 6 analysts, with estimates from -$0.09 to -$0.05.
How often does MXCT beat earnings estimates?
MaxCyte beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +16.77%.
MXCT pages: Overview, Earnings, Forecast, Financials, Competitors, Government Contracts